Nicholas Rhys Medjeral-Thomas, Christopher Lawrence, Marie Condon, Bhrigu Sood, Paul Warwicker, Heather Brown, James Pattison, Sunil Bhandari, Jonathan Barratt, Neil Turner, H. Terence Cook, Jeremy B. Levy, Liz Lightstone, Charles Pusey, Jack Galliford, Thomas D. Cairns, and Megan Griffith: Randomized, Controlled Trial of Tacrolimus and Prednisolone Monotherapy for Adults with De Novo Minimal Change Disease: A Multicenter, Randomized, Controlled Trial. Clin J Am Soc Nephrol 15: 209–218, 2020; DOI: https://doi.org/10.2215/CJN.06180519.
Because of author error, on page 212 of the above-referenced article, the percentage in boldfaced font was inadvertently written as 11% instead of 1%. In the following, the correct percentage is indicated in situ in the section from the article.
There was no significant difference between the tacrolimus and prednisolone cohorts in the proportion of patients who relapsed after achieving complete remission (Table 2). Relapse after complete remission was recorded in 17 out of 23 in the prednisolone cohort, and 16 out of 22 in the tacrolimus cohort (P=0.99; difference in relapse rates, 1%; 95% CI, −22% to 26%).
In the final paragraph of the methods section, the text below incorrectly cited reference 39 instead of a citation that was erroneously missing: “The expected complete remission rate for patients treated with corticosteroids at 8 weeks was estimated at 60% (23), and tacrolimus at 84% (39).” This text should have instead cited the following article: Gulati, S, Prasad, N, Sharma, RK, Kumar, A, Gupta, A, Baburaj, VP: Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant, 23: 910–913, 2008.